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Abstract
Objectives: To assess the impact of long-term pharmacotherapy with guanfacine immediate- or extended-release (GXR),
administered alone or as an adjunctive to a stimulant, on weight and height in children and adolescents with attention-deficit/
hyperactivity disorder (ADHD).
Methods: Data were extracted from U.S. Department of Defense medical records for patients 4–17 years of age at index date
(initiation of any study medication following a year without ADHD medications, or diagnosis if unmedicated) with
weight/height measurements for the analysis period ( January 2009–June 2013) and the previous year (baseline). Longitudinal
weight and height z-scores were analyzed using multivariable regression in three cohorts: guanfacine (initial period of
guanfacine exposure), first-line stimulant monotherapy (initial period of exposure), and unmedicated. Guanfacine cohort
subgroups were based on previous/concurrent stimulant exposure.
Results: The weight analyses included 47,910 patients (66.8% male) and the height analyses 41,248 (67.2% male). Mean
initial exposure in the weight analyses was 237 days (standard deviation [SD] = 258, median = 142) for guanfacine and 257
days (SD = 284, median = 151) for first-line stimulant monotherapy, and was similar in the height analyses. Modeling
indicated that guanfacine monotherapy was not associated with clinically meaningful deviations from normal z-score
trajectories for weight (first-line, n = 943; nonfirst-line, n = 796) or height (first-line, n = 741; nonfirst-line, n = 644). In patients
receiving guanfacine adjunctive to a stimulant, modeled weight (n = 1657) and height (n = 1343) z-scores followed declining
trajectories. In this subgroup, mean standardized weight/height had decreased during previous stimulant monotherapy. For
first-line stimulant monotherapy, modeled weight (n = 32,999) and height (n = 28,470) z-scores followed declining trajec-
tories during year 1. In the unmedicated cohort, modeled weight (n = 11,515) and height (n = 10,050) z-scores were stable.
Conclusions: Guanfacine monotherapy (first-line or nonfirst-line) was not associated with marked deviations from normal
growth in this modeling study of children and adolescents with ADHD. In contrast, growth trajectories followed an initially
declining course with stimulants, whether given alone or with adjunctive guanfacine.
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Introduction
Guanfacine extended release (GXR) is a long-actingnonstimulant treatment for patients with attention-deficit/
hyperactivity disorder (ADHD) (Biederman et al. 2008b; Sallee
et al. 2009b). GXR is approved for use in children and adolescents
6–17 years of age with ADHD, as a monotherapy and as adjunctive
therapy to stimulants in the United States and Canada; as a
monotherapy in Japan; and as a monotherapy in Europe when
stimulants are not suitable, are not tolerated, or have been shown to
be ineffective (Shionogi & Co. Ltd 2017; Shire Pharma Canada
ULC 2019; Shire Pharmaceuticals Ltd. 2017; Shire US, Inc. 2018).
The European Medicines Agency (EMA) recommends moni-
toring weight and height in children and adolescents receiving
stimulants for ADHD because of concerns about growth retardation
(European Medicines Agency 2009, 2014). In contrast, concerns
about weight gain and obesity underlie the EMA recommendation
to monitor weight, height, and body mass index (BMI) regularly in
patients receiving GXR (European Medicines Agency 2015; Shire
Pharmaceuticals Ltd. 2017).
In two 2-year U.S. clinical trials of GXR (doses up to 4 mg/day)
administered as monotherapy or adjunctive to a stimulant, mean
weight, height, and BMI percentiles in children and adolescents with
ADHD were stable at 12 months (Shire US, Inc. 2018), but increases
in weight were reported as GXR-related treatment-emergent adverse
events (TEAEs) in 7.1% (17/240) and 2.3% (6/259) of participants
(Biederman et al. 2008a; Sallee et al. 2009a). In a 2-year European
trial of GXR monotherapy (doses up to 7 mg/day) mean weight,
height, and BMI z-scores remained stable throughout. At the indi-
vidual level, one participant withdrew as a result of a GXR-related
TEAE of weight increase, 13.0% of participants (27/207) shifted to a
higher BMI category, and 8.2% (17/207) shifted to a lower category
(categories were defined as <5th, ‡5th to <85th, ‡85th to <95th, and
‡95th percentile of the 2000 U.S. Centers for Disease Control and
Prevention [CDC] reference population) (Huss et al. 2018).
In shorter trials, no abnormal changes in weight or height were
reported at the group or individual level with GXR or guanfacine
immediate release in children and adolescents with ADHD (Chappell
et al. 1995; Horrigan et al. 1995; Hunt et al. 1995; Scahill et al. 2001;
Biederman et al. 2008b; Sallee et al. 2009b; Hervas et al. 2014;
Wilens et al. 2015; McCracken et al. 2016; Newcorn et al. 2016).
The study reported here was the first to assess the impact of
pharmacotherapy with guanfacine on weight and height in children
and adolescents with ADHD as observed retrospectively in a real-
world clinical setting. The primary objective was to analyze longi-
tudinal measurements of age- and gender-standardized weight and
height in patients receiving any formulation of guanfacine as: first-
line guanfacine monotherapy; nonfirst-line guanfacine monotherapy
(following treatment with a stimulant medication); or guanfacine
adjunctive to stimulant treatment. Similar analyses of patients re-
ceiving first-line stimulant monotherapy and patients not receiving
ADHD pharmacotherapy provided context for the guanfacine results.
Post hoc analyses assessed the impact of guanfacine or stimulant
treatment initiation on standardized weight and height in treatment-
naive patients, and the proportions of guanfacine-treated individuals
with a clinically meaningful shift in standardized weight or height.
Methods
Data extracts and study medications
This retrospective, longitudinal, observational study used data
from anonymized electronic medical records (EMRs) from the U.S.
Department of Defense Military Health System (MHS), which
provides health care to military families stationed in the United
States and overseas. Weight and height measurements were not
recorded in the MHS until October 2008, but data from January 1,
2003 to June 30, 2013 were extracted to provide historical infor-
mation on diagnosis and treatment.
The primary analyses assessed the impact of guanfacine treatment
regimens on change in standardized weight and height z-scores and
were based on a data extract of EMRs that included a prescription for
guanfacine (any immediate release formulation or GXR; no distinc-
tion was made between different guanfacine formulations). Subse-
quently, two control cohorts were derived from a separate data extract
of EMRs that included an ADHD diagnosis: those with a prescription
for first-line stimulant monotherapy (any formulation of amphetamine
or methylphenidate) and those with no prescriptions for an ADHD
medication (any formulation of guanfacine, a stimulant, or atomox-
etine). ADHD was defined according to codes 314.0, 314.00, and
314.01 of the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) 2013 (National Center for Health
Statistics and the Centers for Medicare and Medicaid Services 2013).
Study dates
The study period was January 1, 2009–June 30, 2013. The index
date was defined as the first date during the study period on which
patients received a prescription for a study medication (any for-
mulation of guanfacine or a stimulant) or an ADHD diagnosis (for
patients with no documented prescriptions for a study medication
during the study period).
A guanfacine initiation date was also defined for patients receiv-
ing guanfacine during the study period. The baseline period was
defined as the 12 months before the guanfacine initiation date for
patients receiving guanfacine during the study period, or as the 12
months before the index date for all other patients. The initial period
of exposure to a study medication was defined as the period between
the guanfacine initiation date (for patients receiving guanfacine
during the study period), or the index date (all other patients), and the
date of discontinuation or change in ADHD pharmacotherapy regi-
men, or censoring of observations. Observations were censored when
the patient reached 20 years of age, at the end of the study period, or
at loss to follow-up, whichever occurred first.
In assessing discontinuation, gaps between study medication
prescriptions of up to 30 days during the months of September to
May and up to 121 days during the months of June to August were
allowable to account for delays in renewing prescriptions and for
drug holidays (structured treatment interruptions). For longer gaps,
the patient was considered to have discontinued on the last day
covered by the prescription that preceded the gap, under the as-
sumption that medication was taken as indicated until all dispensed
drug had been consumed.
Study participants
Included patients had a diagnosis of ADHD (at any time), were
4–17 years of age on the index date, had an EMR extending to at
least 12 months before the index date, and had no prescriptions for
an ADHD medication (a study medication or any formulation of
atomoxetine) in the 12 months before the index date. Included
patients also had a baseline weight or height measurement (the most
recent from the baseline period), and at least one eligible post-
baseline measurement.
Weight and height z-scores adjusted for age and gender were
calculated according to the 2000 CDC growth charts for children
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and adolescents 2–20 years of age and the methods provided by the
CDC (Kuczmarski et al. 2002; Flegal et al. 2013). Eligible post-
baseline measurements were within the range -4.5 £ z£ 4.5 (rea-
sonableness test) and occurred during the initial period of exposure
to guanfacine (for patients with a guanfacine prescription) or a
stimulant (for patients with a stimulant prescription but no guan-
facine prescription), or during the postbaseline period (for patients
not receiving ADHD pharmacotherapy).
Study cohorts
Patients were assigned to one of three cohorts according to the
study medications they were prescribed during the study period:
guanfacine, first-line stimulant monotherapy, or unmedicated
(Table 1 and Fig. 1). No matching was conducted between the
cohorts. The guanfacine cohort was divided into three subgroups
based on patients’ stimulant exposure before or during the initial
period of guanfacine exposure: first-line guanfacine monotherapy,
nonfirst-line guanfacine monotherapy, and combined pharmaco-
therapy (Table 1 and Fig. 1).
Prescribed amount and adherence
The prescribed amount (in days) of a particular drug at a spec-
ified dose was defined as the sum of the length of all such pre-
scriptions, ignoring overlaps (e.g., 4 prescriptions for GXR
4 mg/day at 30 days each = 120 days). The total prescribed amount
(in days) of a study medication (i.e., guanfacine or stimulant) was
defined as the sum of the prescribed amount of each particular drug
at a specified dose, with overlaps of prescriptions for different drugs
and/or doses capped at 90 days (Fig. 2). Adherence to a medication
class was measured using the medication possession ratio (MPR),
defined as the total prescribed amount (in days) of the study med-
ication during the initial period of exposure, divided by the total
number of days in the initial period of exposure, capped at 100%.
Statistical analyses
In this retrospective database study, no a priori power or sample
size estimates were performed and no adjustments to alpha were
made to control for multiple comparisons. All p-values are there-
fore nominal.
Analyses of longitudinal weight and height z-scores
Multivariable regression (random coefficients mixed-model
analysis with multiple covariates [described in the following two
paragraphs]) was carried out in SAS version 9.3 (SAS Institute,
Inc., Cary, NC). Each cohort was analyzed separately and six
models were constructed per cohort, three with weight z-score as the
response variable and three with height z-score (all patients, males,
and females). An unstructured covariance matrix was used for the
random effects (intercept, and linear and quadratic time from the
guanfacine initiation date [guanfacine cohort] or from the index date
[other cohorts]). Several spatial covariance structures conceptually
similar to an autoregressive structure (without the equal spacing
assumption) were examined in addition to the unstructured matrix
that was ultimately used. Fixed-effect predictor variables (see the
following two paragraphs) represented characteristics of patients or
of ADHD medications received before or during the period covered
by the regression analyses. There were no issues with model con-
vergence and the unstructured covariance model was considered
adequate. No variables were removed from the models.
Analyses of the guanfacine cohort used the baseline weight or
height measurement (with the time of the measurement imputed to
time= 0), and all weight or height measurements recorded during
the initial period of guanfacine exposure and the 60 days afterward.
Each model included the following fixed-effect predictor variables:
age at baseline measurement (continuous), gender (binary; ‘‘all
patients’’ model only), guanfacine MPR during the initial period of
guanfacine exposure (continuous), stimulant prescribed amount
(in days) preguanfacine (continuous), use of atomoxetine before
guanfacine exposure (binary), use of atomoxetine during guanfa-
cine exposure (binary), and guanfacine cohort subgroup (categor-
ical). The inclusion of an interaction term between time and
subgroup allowed the trajectories for each subgroup to follow
differently shaped paths.
Analyses of the first-line stimulant monotherapy and unmedicated
cohorts used the baseline weight or height measurement (with the
time of the measurement imputed to time=0), and all weight or
height measurements recorded in the initial period of stimulant ex-
posure and the 60 days afterward (first-line stimulant monotherapy
cohort), or all weight or height measurements from the index date
until censoring of observations (unmedicated cohort). Each model
included the following fixed-effect predictor variables: age at base-
line measurement (continuous), gender (binary, ‘‘all patients’’ models
only), and stimulant MPR during the initial period of stimulant ex-
posure (continuous, first-line stimulant monotherapy models only).
Post hoc analyses of the impact of ADHD treatment
initiation on growth
The impact of ADHD treatment initiation in treatment-naive
patients was assessed in separate post hoc regression analyses.
Patients in the first-line guanfacine monotherapy subgroup, the
Table 1. Study Cohorts and Subgroups
Study cohort/subgroup Definition
Guanfacine cohort At least one prescription for guanfacine (any formulation)
First-line guanfacine
monotherapy subgroup
First study medication was guanfacine, with no simultaneous stimulant prescription
Nonfirst-line guanfacine
monotherapy subgroup
Stimulant exposure ended before or up to 28 days after first guanfacine prescription (Fig. 1)
Combined pharmacotherapy
subgroup
First guanfacine prescription was simultaneous with a stimulant prescription or concurrent with
stimulant exposure for more than 28 days (Fig. 1)
First-line stimulant monotherapy
cohort
At least one prescription for a stimulant but no prescription for guanfacine at any time
Unmedicated cohort No prescribed ADHD medications
ADHD, attention-deficit/hyperactivity disorder.
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first-line stimulant monotherapy cohort, and the unmedicated co-
hort were included in separate models, using the same weight or
height measurements as the earlier analyses. Each model included a
binary predictor variable to indicate whether a weight or height
measurement was made before or on/after the index date, with
linear and quadratic time at measurement as random effects.
Post hoc analyses of individual weight or height
z-score shifts in the guanfacine cohort subgroups
Individual weight or height z-score shifts between the baseline
measurement and the last measurement included in the regression
analyses were analyzed post hoc in the guanfacine cohort subgroups.
In the absence of guanfacine-specific recommendations for poten-
tially clinically meaningful shifts, the criteria recommended for
monitoring stimulant-treated individuals in the American Academy
of Child and Adolescent Psychiatry (AACAP) Practice Parameter
for the Assessment and Treatment of Children and Adolescents with
ADHDwere used, namely a shift in weight or height z-score crossing
two percentile lines on a chart showing the 5th, 10th, 25th, 50th, 75th,
90th, and 95th percentiles (Pliszka et al. 2007). Because weight and
height measurements were not always concurrent, these exploratory
analyses were unable to examine whether such shifts were from/to a
healthy or unhealthy BMI category.
Guanfacine cohort
First-line stimulant monotherapy cohortd
Unmedicated cohorte
First-line monotherapy subgroupa
Non-first-line monotherapy subgroupb
Combined pharmacotherapy subgroupc
Stimulant (continuous) 
Guanfacine (continuous)
Study medications
Stimulant
(need not be continuous)  
> 28 days 
£ 28 days
Baseline periodf
Initial period
of exposure
Study time periods
Time = 0g (start of 
regression analyses)
Index date coincides
with guanfacine
initiation date
Index date 
Guanfacine
initiation date
Study dates
FIG. 1. Study cohorts. aFirst study medication is guanfacine monotherapy; subsequent stimulant prescriptions permissible. bStimulant
exposure ended before or up to 28 days after first guanfacine prescription. Index date (stimulant initiation) could predate the start of the
baseline period. Stimulant exposure before guanfacine initiation need not be continuous. cFirst guanfacine prescription simultaneous
with a stimulant prescription or concurrent with stimulant exposure for more than 28 days. Initial period of exposure ends at discon-
tinuation of guanfacine and/or stimulant. Index date (stimulant initiation) could predate the start of the baseline period and stimulant
exposure before guanfacine initiation need not be continuous. dFirst study medication is stimulant monotherapy; no guanfacine
prescription at any time. eNo prescriptions for any ADHD medication (a study medication or atomoxetine). fBaseline measurement is the
most recent weight or height measurement during the baseline period (the 12 months before time = 0). gGuanfacine initiation date in the
guanfacine cohort, index date in other cohorts. ADHD, attention-deficit/hyperactivity disorder.
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Results
Index date demographics and clinical characteristics
The weight analyses included 3396, 32,999, and 11,515 patients
in the guanfacine, first-line stimulant monotherapy, and unmedi-
cated cohorts, respectively, with 2728, 28,470, and 10,050 in the
height analyses, respectively. Demographic characteristics at the
index date were generally similar between the cohorts for the
weight analyses (Table 2) and height analyses (Supplementary
Table S1).
A lower proportion of patients receiving first-line guanfacine
monotherapy had an ADHD diagnosis on or before their index date
compared with those who received a stimulant on their index date,
and higher proportions of patients in the overall guanfacine cohort
had autism spectrum disorder or anxiety than in the other cohorts
(Table 2 and Supplementary Table S1). A higher proportion of
patients in the guanfacine cohort were 9 years of age or under on
their index date than in the first-line stimulant monotherapy or
unmedicated cohorts (82.6%, 60.8%, and 64.2%, respectively, in
the weight analyses; Table 2). Similar proportions of patients were
exposed to corticosteroids across the cohorts, whereas a higher
proportion of patients in the guanfacine cohort than in other cohorts
were exposed to antiepileptic medications (Table 2 and Supple-
mentary Table S1).
Exposure to ADHD medications
In the guanfacine and first-line stimulant monotherapy cohorts,
the mean initial period of exposure to guanfacine or a stimulant,
respectively, was*8 months, with high variance (standard deviation
[SD] *9 months), giving a mean time in the analysis of *10
months. Patients in the guanfacine cohort with previous (or concur-
rent) stimulant exposure had initiated stimulant a mean of*12–13
months (SD*11 months) before initiating guanfacine (Table 3).
Weight and height z-scores at index date and baseline
Mean weight and height z-scores at the index date (i.e., when
ADHD-medication naive) were similar across cohorts and higher
than the reference population mean (0) (not shown). By the time of
the baseline measurement, weight and height z-scores were sub-
stantially lower in patients in the guanfacine cohort with previous
(or concurrent) stimulant exposure (Table 4). For example, in the
combined pharmacotherapy subgroup, mean weight z-score in
males fell from 0.362 (95% confidence interval [0.303–0.421]) at
the index date (last measurement before stimulant initiation) to
-0.075 [-0.138 to -0.013] at baseline (last measurement before
guanfacine initiation), and mean height z-score fell from 0.231
[0.165–0.298] to 0.009 [-0.057 to 0.076]. Similar trends were seen
in the nonfirst-line guanfacine monotherapy subgroup (not shown).
The mean time between the baseline measurement and the start
of the regression analyses was *2–3 months across all cohorts,
with high variance (SD*2–3 months) (Table 4).
Availability of measurements
Approximately half of patients had at least three postbaseline
measurements (Table 4), but by the end of year 1, 14.2%, 15.9%,
and 54.1% of patients remained in the weight analyses in the
guanfacine, first-line stimulant monotherapy, and unmedicated
cohorts, respectively, with lower proportions remaining in the
Total prescribed amount of a study medicationa = T1 + T2 days
Total prescribed amount of a study medicationa = T1 + T2 days
Total prescribed amount of a study medicationa = T1 + T2  2(To  90) days
Overlap £ 90 days
Overlap, T
o
 > 90 days
T1 Tsyad 2 days
Drug A: dose 2, or
Drug B: any dosecDrug A, dose 1
b
a
b
c
T1 days
T1 Tdays 2 days
T2 days
FIG. 2. Calculation of prescribed amount (in days) of a study medication for different drugs or for different doses of the same
drug: with no overlaps between prescriptions (a), with overlaps £90 days (b), or with overlaps >90 days (c). aStudy medications:
guanfacine (any formulation of GXR or GIR); stimulant (any formulations of amphetamine or methylphenidate). bFor example,
GXR 4 mg/day. cFor example, GXR <> 4 mg/day or GIR any dose. GIR, guanfacine immediate release; GXR, guanfacine extended
release.
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height analyses (Figs. 3 and 4). Trends beyond 1 year in the
guanfacine and first-line stimulant monotherapy cohorts should
therefore be interpreted with caution, owing to the small proportion
of patients remaining in the analysis and the high rate of drop-out
compared with the unmedicated cohort (see Discussion section).
Modeled (group level) weight and height
z-score trajectories
Guanfacine monotherapy was not associated with clinically
meaningful changes in modeled weight or height z-score trajectories,
FIG. 3. Modeled z-scores for weight (a–c) and height (d–f) in the guanfacine cohort for all patients (a, d), males (b, e), and females
(c, f). Solid lines show the trajectories when all other predictor variables are held constant to their overall means for patients in the
guanfacine cohort, apart from ‘‘stimulant supply preguanfacine,’’ which is held constant to the mean of each subgroup. Traces show a
random sample of patients. Numbers below the x axes indicate the numbers of patients with weight/height measurements on or after
each time point.
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either when administered first-line or when administered nonfirst
line (Fig. 3). In the combined pharmacotherapy subgroup (guan-
facine and a stimulant), modeled weight and height z-score tra-
jectories followed declining courses that were significantly
different in shape from those in the first-line guanfacine mono-
therapy subgroup, as indicated by the model interaction term
( p < 0.0001; Tables 5, 6 and Fig. 3).
In separate analyses stratified by sex, modeled trajectories for
combined pharmacotherapy remained stable in females (Fig. 3c, f)
(weight, p= 0.3354; height, p= 0.1027 vs. first-line guanfacine
monotherapy) and declined in males (Fig. 3b, e) (weight, p< 0.0001;
height, p<0.0001 vs. first-line guanfacine monotherapy).
Following initiation of first-line stimulant monotherapy, mod-
eled weight z-scores followed a declining trajectory for the first 1–2
FIG. 4. Modeled z-scores for weight (a–c) and height (d–f) in the first-line stimulant monotherapy and unmedicated cohorts for all
patients (a, d), males (b, e), and females (c, f). Solid lines show the trajectories when all other predictor variables are held constant to the
mean of each cohort. Traces show a random sample of patients. Numbers below the x axes indicate the numbers of patients with
weight/height measurements on or after each time point.
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years (Fig. 4a–c and Table 7). Modeled height z-scores tended to
decline for *3–4 years (Fig. 4d–f and Table 8). In unmedicated
patients, weight and height z-scores remained stable over time
(Fig. 4 and Tables 9, 10).
Relationships after controlling for all other model
variables, including time
In the guanfacine cohort, a greater prescribed amount (in days)
of stimulant before initiating guanfacine was a significant predictor
of lower weight z-scores (all patients p< 0.0001; males p < 0.0001;
females p = 0.0048; Table 5), and also of lower height z-scores in all
patients and in males ( p< 0.0001; Table 6). In the first-line stim-
ulant monotherapy cohort, stimulant adherence (as measured by
MPR) was a significant predictor of higher height z-score in all
patients and in males ( p = 0.0046 and 0.0255, respectively;
Table 8).
Guanfacine adherence, as measured by MPR, did not have a
significant effect on weight or height z-score (e.g., all patients,
weight p= 0.4863; height p= 0.3513; Table 5). Similarly, exposure
to the nonstimulant atomoxetine before or during guanfacine ex-
posure was not a significant predictor of weight or height z-score
(Table 5).
A greater age at baseline measurement was a significant pre-
dictor of higher weight z-score in each of the all-patient models
(guanfacine, p= 0.0069; first-line stimulant monotherapy, p <
0.0001; unmedicated, p< 0.0001; Tables 5, 7, and 9). Males had
significantly higher weight and height z-scores than females
(weight: guanfacine, p = 0.0007; first-line stimulant monotherapy,
p = 0.0002; unmedicated, p< 0.0001; height: guanfacine, p =
0.0260; first-line stimulant monotherapy, p < 0.0001; unmedicated,
p < 0.0001; Tables 5–10).
Post hoc analyses of the impact of ADHD treatment
initiation on growth
First-line guanfacine monotherapy was associated with signifi-
cantly higher weight z-scores after treatment compared with before
treatment in males (p<0.0001) but not in females ( p=0.19), ac-
cording to the model with the binary predictor variable (Table 11).
The magnitude of the increase in weight in males was*0.06 of the
reference population SD. First-line stimulant monotherapy was as-
sociated with significantly lower weight and height z-scores after
treatment compared with before treatment (p<0.0001, Table 11). The
effect of stimulant monotherapy on weight z-score was greater than its
effect on height z-score, with decreases of *0.14 and 0.025 of the
reference population SD, respectively. In the unmedicated cohort,
weight and height z-scores did not change significantly after ADHD
diagnosis compared with before diagnosis (p‡0.22, Table 11).
Post hoc analyses of individual z-score shifts
in the guanfacine cohort subgroups
A numerically higher proportion of patients receiving guanfa-
cine monotherapy had a positive weight z-score shift (4.4%) than a
negative shift (2.0%), in contrast to combined pharmacotherapy
(positive shift 3.1%, negative shift 4.1%) (Table 12).
Discussion
This large database study is the first to present an analysis of
longitudinal growth trajectories in children and adolescents with
ADHD receiving guanfacine in a real-world clinical setting. The
models covered a time period of over 3 years, but data became
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increasingly sparse with elongated follow-up beyond 1 year in
cohorts receiving an ADHD medication and the mean analysis
period was*10 months. Thus, trends observed during the first year
of the study are more reliable than later trends.
With guanfacine monotherapy, administered first-line or fol-
lowing stimulant treatment, modeled standardized weight and
height z-score trajectories followed those of the reference popula-
tion norms (i.e., were approximately horizontal) (Kuczmarski et al.
2002). A post hoc model indicated that treatment-naive males had
significantly higher weight z-scores after starting guanfacine,
compared with before. This group-level increase equates to a gain
of 0.8 kg for a 17-year-old male and less for younger children
(Kuczmarski et al. 2002), and would not qualify as a z-score shift
based on recommendations from AACAP (see Methods section)
(Pliszka et al. 2007).
A separate post hoc analysis of individual weight z-score shifts
based on the AACAP recommendations showed a potentially clini-
cally meaningful increase in 4.4% of patients receiving guanfacine
monotherapy, and a potentially clinically meaningful decrease in
2.0%. The proportion with an increase was of a similar order of
magnitude to the proportion of patients in long-term clinical trials for
whom GXR-related TEAEs of weight increase were reported (Bie-
derman et al. 2008a; Sallee et al. 2009a; Huss et al. 2018).
In the first-line stimulant monotherapy cohort, modeled stan-
dardized weight trajectory declined during the first 1–2 years of
treatment, with a less pronounced decline in standardized height,
consistent with the known side effects of stimulant medications.
A post hoc model indicated that individuals in the first-line stim-
ulant monotherapy cohort had significantly lower weight and
height z-scores after initiating stimulant therapy, compared with
before. These group-level deficits were equivalent to*1.6 kg and
0.2 cm at the age of 17 years (Kuczmarski et al. 2002) and would
not qualify as a potentially clinically meaningful z-score shift based
on the AACAP recommendations (Pliszka et al. 2007).
The initial trends in the first-line stimulant monotherapy cohort
are consistent with the results of a quantitative analysis of 20 lon-
gitudinal studies of children and adolescents with ADHD receiving
stimulant monotherapy with at least 1 year of follow-up, in which
the authors concluded that stimulant treatment was associated with
slower-than-expected increases in weight and height, an effect that
attenuated over time (Faraone et al. 2008). Similarly, more indi-
viduals shifted to a lower than to a higher weight, height, or BMI z-
score category in a recently published 2-year trial of open-label
lisdexamfetamine dimesylate (Coghill et al. 2017; Banaschewski
et al. 2018). Long-term observational follow-up of participants in
the Multimodal Treatment Study of children with ADHD (n= 515)
and controls (n = 289) indicates that extended use of stimulants is
associated with suppression of adult height at 25 years of age
(Swanson et al. 2017). In the present study, the fact that greater
stimulant adherence (as measured by MPR) was a significant pre-
dictor of higher height z-scores in the first-line stimulant mono-
therapy cohort may indicate active management by clinicians (i.e.,
fewer structured treatment interruptions occurred if potential height
deficits were not a concern).
In a patient population with reduced mean weight and height
z-scores following previous stimulant monotherapy, modeled stan-
dardized weight and height followed declining trajectories after
augmentation of stimulant treatment with guanfacine. The contin-
ued decline of the model trajectories may, in part, be due to the
imputation of the baseline measurement to time = 0. For individuals
whose z-score decreased between their baseline measurement and
augmentation of the stimulant with guanfacine, the imputation
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would lead to a steeper postbaseline decline than if the time of the
baseline measurement had been included in the model.
In patients with ADHD who did not receive pharmacotherapy,
modeled standardized weight and height trajectories remained
stable over time, suggesting that ADHD itself was not associated
with dysregulated growth at the group level. In a study from the
1990s, a small attenuation in height z-score was reported in 124
children and adolescents with ADHD compared with healthy
controls; this resolved by late adolescence and was reported to be
unrelated to exposure to ADHD medications (Spencer et al. 1996,
1998), although others have commented that the study is difficult to
interpret owing to lack of information on the length of time on
treatment (Poulton 2005). The results of the present study are
consistent with those of a prospective longitudinal study of children
and adolescents with ADHD (n= 137) and matched controls
(n = 124) who were followed up to a mean age of 22 years. In that
study, the investigators concluded that any delays in expected
growth had resolved by adulthood (Biederman et al. 2010).
Standardized mean weight in treatment-naive children and ad-
olescents with ADHD in the present study was higher than the
population norm, and the models indicated that older patients
tended to have higher standardized weight than younger patients.
These findings could reflect both the high prevalence of obesity in
children and adolescents with ADHD (Waring et al. 2008) and the
fact that the most recent data used to generate the reference pop-
ulation norm z-scores are from 1980 (Kuczmarski et al. 2002), so do
not capture the increasing prevalence of obesity overall and with
age in the general U.S. and MHS database populations (Eilerman
et al. 2014; National Center for Health Statistics 2016; Skinner
et al. 2018).
Strengths of this retrospective review include the availability of
large numbers of real-world patient records spanning long time
periods. The first-line stimulant monotherapy and unmedicated
cohorts were much larger than in previous studies of longitudinal
weight or height z-scores in children and adolescents with ADHD
(Faraone et al. 2008; Dura-Trave et al. 2012; Kim et al. 2014). In
addition, the majority of patients were 9 years of age and under at
the index date (Table 2 and Supplementary Table S1), allowing
weight and height to be assessed during a period of rapid growth.
Moreover, the study population contained a broader sample of
patients than were included in long-term clinical trials of GXR
monotherapy (Biederman et al. 2008a; Sallee et al. 2009a; Huss
et al. 2018), for example, patients 4–5 years of age, those with
psychiatric comorbidities, and those of all weights. Finally, uni-
versal access to care in the MHS may favor compliance with
medications.
A number of caveats, however, should be noted regarding the
patient population. First, care should be taken in applying these
results in other jurisdictions, given that the ICD diagnostic criteria
used in the present study identify a narrower subset of severely
affected individuals than the Diagnostic and Statistical Manual of
Mental Disorders (DSM) Fourth Edition (American Psychiatric
Association 2000) or DSM Fifth Edition (American Psychiatric
Association 2013) criteria (Santosh et al. 2005; National Institute
for Health and Care Excellence 2018) and compliance with pre-
scribed medications may be different in non-MHS patients. Second,
children with potential growth/maturation issues may have been
more likely to have baseline and longitudinal weight or height
measurements and more frequent health care visits, and therefore to
be included in the analyses, than children without. The same is true
of younger children, compared with older children/adolescents.
Third, children of military personnel tend to be younger and to
have a lower prevalence of obesity than children in the general U.S.
population (United States Census Bureau 2016; Eilerman et al.
2014; U.S. Department of Defense 2014). Finally, deployment of a
military parent for extended periods of time is known to be asso-
ciated with reduced frequency of switching between ADHD med-
ications and increased frequency of mental/behavioral health care
visits compared with when the parent is at home (Hisle-Gorman
et al. 2014).
The study design and type of models employed also lead to
limitations in interpretation. First, the models did not control for
some factors that may have affected outcomes, in particular med-
ications known to affect growth (Table 2 and Supplementary
Table S1). Inhaled corticosteroid use in children with mild-to-
moderate asthma leads to reduced height gain, with a trend toward
greater reductions at higher doses (Loke et al. 2015), and height
deficits persist into adulthood (Childhood Asthma Management
Program Research Group et al. 2000; Kelly et al. 2012). With the
antiepileptic medications most commonly prescribed in the guan-
facine cohort, valproate/valproic acid and oxcarbazepine, weight
gain is a commonly reported concern (Verrotti et al. 2009; Petty
et al. 2014; Hamed 2015; Garoufi et al. 2016), and valproate has
also been reported to reduce height gain (Lee et al. 2013). The
design of present analyses, however, meant that time-varying
covariates, such as exposure to other medications, could not be
included. Moreover, medication dosage and route of administration
were not captured and asthma severity is not coded in the ICD-9-
CM system (National Center for Health Statistics and the Centers
for Medicare and Medicaid Services 2013). Other factors not
controlled for included comorbidities, ADHD severity, ADHD
medication dosage, parental military rank, periods of parental
Table 12. Post Hoc Analyses of Individual Weight or Height z-Score Shiftsa
in the Guanfacine Cohort Subgroups (n, %)
First-line monotherapy subgroup Nonfirst-line monotherapy subgroup Combined pharmacotherapy subgroup
Weight analyses Males, n= 666 Females, n= 277 Males, n= 591 Females, n = 205 Males, n= 1240 Females, n= 417
Increase 29 (4.35%) 13 (4.69%) 26 (4.40%) 9 (4.39%) 40 (3.23%) 11 (2.64%)
Decrease 13 (1.95%) 7 (2.53%) 9 (1.52%) 6 (2.93%) 47 (3.79%) 21 (5.04%)
Height analyses Males, n= 528 Females, n= 213 Males, n= 478 Females, n = 166 Males, n= 1011 Females, n= 332
Increase 30 (5.68%) 5 (2.35%) 16 (3.35%) 4 (2.41%) 28 (2.77%) 7 (2.11%)
Decrease 20 (3.79%) 8 (3.76%) 28 (5.86%) 11 (6.63%) 45 (4.45%) 16 (4.82%)
az-score shifts are defined as a change in weight or height that crosses two percentile lines on a chart showing the 5th, 10th, 25th, 50th, 75th, 90th, and
95th percentiles, based on the AACAP Practice Parameter for the Assessment and Treatment of Children and Adolescents with ADHD (Pliszka et al.
2007). The present analyses used the shift between the baseline measurement and the last measurement included in the regression.
AACAP, American Academy of Child and Adolescent Psychiatry; ADHD, attention-deficit/hyperactivity disorder.
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deployment, ethnicity, and location. In particular, compared with
the other cohorts, the guanfacine cohort contained higher propor-
tions of individuals with conditions for which drugs associated with
antipsychotic weight gain may be prescribed (Musil et al. 2015),
such as depression, anxiety, and autism spectrum disorders (Table 2
and Supplementary Table S1).
Second, calculated z-scores for individuals whose weight or
height lie outside the CDC reference population 3rd and 97th
percentiles (z= – 1.88) are known to be unreliable (Kuczmarski
et al. 2002; Flegal et al. 2009, 2013).
Third, the models could not distinguish between stimulant use
before the baseline measurement and stimulant use between the
baseline measurement and guanfacine initiation date because the
measurement was imputed to time = 0.
Fourth, the sample included patients whose data could not
contribute to the trajectory analyses because their only postbaseline
measurement also occurred at time = 0. This may have affected up
to a quarter of patients receiving pharmacotherapy (Table 4), if
their weight and height were measured on the day they were first
prescribed a new study medication.
Fifth, the first-line stimulant monotherapy cohort did not include
patients who later received guanfacine, so the trends observed may
not apply to all treatment-naive children and adolescents with
ADHD who start stimulant treatment. In particular, patients for
whom first-line stimulant monotherapy was ineffective, poorly
tolerated, or impacted on growth or cardiovascular health are more
likely to appear in the combined pharmacotherapy or nonfirst-line
guanfacine monotherapy subgroups than in the first-line stimulant
monotherapy cohort.
Finally, the cohorts were not included in the same model. This
means that they cannot be compared directly—for example,
between-cohort differences, such as the younger mean age in the
guanfacine cohort, could not be controlled for.
Another limitation is the high level of drop-out, meaning that
trends at later time points were based on far fewer patients than
trends at earlier time points. Although longitudinal regression re-
sults are minimally affected by randomly occurring drop-out, they
can become seriously biased when drop-out is predicted by baseline
or response variables (Gustavson et al. 2012). In the present study,
the drop-out rate was higher in the medicated cohorts than in the
unmedicated cohorts (Figs. 3 and 4), suggesting that medication use
affected the likelihood of drop-out, and therefore indicating po-
tential for bias. Furthermore, the risk of bias is especially great
when the response variable (in this case weight or height z-score)
for those remaining is within an ‘‘acceptable’’ range as time pro-
gresses (Howell 2007). In the present study, the possibility of
treating physicians discontinuing or switching patients’ medication
because of growth concerns represents a second source of poten-
tially serious bias in the regression models.
Conclusions
Guanfacine monotherapy given first-line or following a stimu-
lant was not associated with marked deviation from a normal
growth trajectory at the group level in this large, retrospective re-
gression modeling study of children and adolescents with ADHD.
At the individual level, fewer than 5% of patients had a potentially
clinically meaningful increase in weight, based on z-score shifts.
The study confirmed that stimulant therapy, with or without
guanfacine augmentation, is associated with slower-than-expected
growth during the first year of treatment at the group level.
Clinical Significance
These findings support current recommendations for regular
monitoring of patients’ weight and height to assess the potential
impact of ADHD treatment regimens on growth.
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